Long COVID and Post-Acute COVID-19 Syndrome: Pathophysiology, Clinical Features and Management
Long COVID is a term introduced in 2020 to denote the persistence of symptoms post SARS-CoV-2 nfection. It is characterised by persistent heterogeneous symptoms affecting multiple organ systems.
COVID-19 infection first emerged in Wuhan province, China, in late 2019. [Crook et al., 2021]
Many variants of COVID-19 have now been discovered. The first variant, alpha, was found in Kent, UK, and as of 30 June 2021, it was confirmed in more than 275,000 cases in the UK and spread to at least 136 other countries. [UK Gov, 2021] Other investigated variants include Beta, Gamma, Zeta, Theta, and Kappa. [UK Gov, 2021]
New covid-19 variants will continue to emerge and spread as the pandemic progresses, for example, Eta and Delta, with the delta variant accounting for over 161,000 cases in the UK as of 30 June 2021. [UK Gov, 2021]
The Lambda variant is a more recent strain that needs to be fully evaluated to establish the outcome of any long-term complications. [UK Gov, 2021]
In this article we cover the pathophysiology of long COVID with a greater emphasis on the neuropsychiatric aspects.
Hamming, I., Timens, W., Bulthuis, M. L. C., Lely, A. T., Navis, G. V., & van Goor, H. (2004). Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland, 203(2), 631-637.
Kachaner, A., Lemogne, C., Dave, J., Ranque, B., de Broucker, T., & Meppiel, E. (2022). Somatic symptom disorder in patients with post-COVID-19 neurological symptoms: a preliminary report from the somatic study (Somatic Symptom Disorder Triggered by COVID-19). Journal of Neurology, Neurosurgery & Psychiatry, 93(11), 1174-1180.
Hosseini, A., Badri, T., Esmaeili Gouvarchin Ghaleh, H., Hassanpour, K., Alishiri, G., Akbariqomi, M., & Farnoosh, G. (2022). Melatonin as a complementary and prophylactic agent against COVID-19 in high-risk populations: A narrative review of recent findings from clinical and preclinical studies. Fundamental & Clinical Pharmacology.
Freedberg, D. E., Conigliaro, J., Wang, T. C., Tracey, K. J., Callahan, M. V., Abrams, J. A., … & Landry, D. W. (2020). Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology, 159(3), 1129-1131.